Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo Chinese For Medical Students & Physicians A complete 20-lesson, 300-page Chinese course with a companion app in 21 languages — free forever. Download the free PDF: Amedeo Chinese PDF

Schizophrenia

Free Subscription Articles published in Am J Psychiatry Retrieve available abstracts of 96 articles: HTML format

Single Articles

July 2026
1. VAN DER MEER D, Shadrin AA, Stinson SE, Koch E, et al
   Divergent Patterns of Genetic Overlap Between Severe Mental Disorders and Metabolic Markers.
   Am J Psychiatry. 2026;183:482-493.
   PubMed     Abstract available
   
   
   June 2026
2. FORSYTH JK, Zhu J, Chavannes AS, Trevorrow ZH, et al
   Association of Fetal Gene Regulatory Gene Deletions With Poor Cognition in Schizophrenia and Community-Based Samples.
   Am J Psychiatry. 2026 Jun 24:appiajp20240779. doi: 10.1176/appi.ajp.20240779.
   PubMed     Abstract available
   
   
   
3. LAURSEN AF, Bundgaard AF, Lawaetz Daugaard N, Birk M, et al
   Neurocognitive Development in Adolescent Offspring at Familial High Risk of Schizophrenia or Bipolar Disorder and a Population-Based Control Group.
   Am J Psychiatry. 2026 Jun 24:appiajp20250841. doi: 10.1176/appi.ajp.20250841.
   PubMed     Abstract available
   
   
   
4. VANO LJ, Sedlacik J, Carr RW, Bukala BR, et al
   Gray Matter Iron and Neuromelanin in Psychosis: A Systematic Review and Meta-Analysis of MRI Studies.
   Am J Psychiatry. 2026 Jun 10:appiajp20251257. doi: 10.1176/appi.ajp.20251257.
   PubMed     Abstract available
   
   
   
5. RUBIO JM, Kane JM
   A Proposed Expansion of the Definition of Treatment-Resistant Schizophrenia.
   Am J Psychiatry. 2026 Jun 10:appiajp20251269. doi: 10.1176/appi.ajp.20251269.
   PubMed    
   
   
   
6. YOUSSIM I, Israel S, Calderon-Margalit R, Manor O, et al
   Schizophrenia in Offspring of Holocaust Survivors: Intergenerational Effects of Preconception Parental Trauma Within the Jerusalem Perinatal Study.
   Am J Psychiatry. 2026 Jun 3:appiajp20241145. doi: 10.1176/appi.ajp.20241145.
   PubMed     Abstract available
   
   
   
7. D'SOUZA DC, Cortes-Briones J, Raj J, Ganesh S, et al
   Cognitive, Electrophysiological, and Behavioral Presentation of First-Episode Psychosis With or Without Cannabis Exposure.
   Am J Psychiatry. 2026 Jun 3:appiajp20250726. doi: 10.1176/appi.ajp.20250726.
   PubMed     Abstract available
   
   
   
8. RIZK MM, Mann JJ
   An Update on Somatic Treatments for Suicide Risk.
   Am J Psychiatry. 2026;183:382-400.
   PubMed     Abstract available
   
   
   May 2026
9. UZOIGWE C
   Schizophrenia and Doxycycline: Microbiome Mediator?
   Am J Psychiatry. 2026 May 13:appiajp20251193. doi: 10.1176/appi.ajp.20251193.
   PubMed    
   
   
   
10. KELLEHER I, Lang U, Metsala J, Healy C, et al
    Doxycycline and Schizophrenia: Response to Letters.
    Am J Psychiatry. 2026 May 13:appiajp20260263. doi: 10.1176/appi.ajp.20260263.
    PubMed    
    
    
    
11. DE WITTE LD, Laban M, Bergink V
    Reporting of Sex Specific Findings Leads to Altered Conclusions Regarding Potential Protective Effects of Doxycycline for Schizophrenia.
    Am J Psychiatry. 2026 May 13:appiajp20251277. doi: 10.1176/appi.ajp.20251277.
    PubMed    
    
    
    
12. BLACK KJ
    Doxycycline, Schizophrenia, and Toxoplasmosis.
    Am J Psychiatry. 2026 May 13:appiajp20251231. doi: 10.1176/appi.ajp.20251231.
    PubMed    
    
    
    
13. BORRAZ-LEON JI, Rantala MJ
    Doxycycline and the Parasite x Genotype x Stress Model of Schizophrenia.
    Am J Psychiatry. 2026 May 13:appiajp20251284. doi: 10.1176/appi.ajp.20251284.
    PubMed    
    
    
    April 2026
14. ENWRIGHT JF 3RD, Tamburino AM, Tumkaya T, Lovatt D, et al
    Transcriptional Profiles of Somatostatin and Parvalbumin Interneuron Subtypes in the Human Dorsolateral Prefrontal Cortex: Implications for Schizophrenia.
    Am J Psychiatry. 2026 Apr 22:appiajp20250355. doi: 10.1176/appi.ajp.20250355.
    PubMed     Abstract available
    
    
    
15. KU SH, Stringfield SJ, Torregrossa MM, Sweet RA, et al
    Envisioning Cannabinoid CB1 Receptor Biased Signaling as a Therapeutic Target for Schizophrenia.
    Am J Psychiatry. 2026 Apr 17:appiajp20250886. doi: 10.1176/appi.ajp.20250886.
    PubMed     Abstract available
    
    
    
16. DE LAS CUEVAS C
    Beyond Symptom Thresholds: Toward a Clinically and Culturally Inclusive Definition of Relapse in Schizophrenia.
    Am J Psychiatry. 2026;183:269-270.
    PubMed    
    
    
    
17. NICHOLSON RC, Choi UE, Mojtabai R, Thrul J, et al
    Association of Cannabis Use Disorder Versus Other Substance Use Disorders With Psychiatric Conditions: A Propensity-Matched Retrospective Cohort Analysis.
    Am J Psychiatry. 2026;183:260-268.
    PubMed     Abstract available
    
    
    March 2026
18. MARDER SR
    Finding a Medication for Negative Symptoms in Schizophrenia: Why So Many Failures?
    Am J Psychiatry. 2026;183:154-155.
    PubMed    
    
    
    
19. MYUNG W, Ahn Y, Kim J, Won HH, et al
    Targeted Therapeutic Intervention for Problematic Alcohol Use, Comorbid Depressive Disorder, and Schizophrenia: Response to Lawford and Norrie.
    Am J Psychiatry. 2026;183:216.
    PubMed    
    
    
    
20. LI C, Sun P
    Overlooked Methodological Limitations in the Study of Grip Strength and Default Mode Network Connectivity in Early Psychosis.
    Am J Psychiatry. 2026;183:214.
    PubMed    
    
    
    
21. KALIN NH
    Advances Relevant to Treating Bipolar Disorder, PTSD, and Schizophrenia.
    Am J Psychiatry. 2026;183:149-151.
    PubMed    
    
    
    February 2026
22. KAUL I, Claxton A, Sauder C, Patel T, et al
    Long-Term Safety and Efficacy of Xanomeline and Trospium Chloride in Schizophrenia: A 52-Week Open-Label Extension Trial.
    Am J Psychiatry. 2026 Feb 4:appiajp20241186. doi: 10.1176/appi.ajp.20241186.
    PubMed     Abstract available
    
    
    
23. KALIN NH
    Neuroplasticity, Antipsychotic Efficacy, Schizophrenia Risk Reduction With Doxycycline Exposure, and Cannabis and Alcohol Use Interactions.
    Am J Psychiatry. 2026;183:87-89.
    PubMed    
    
    
    December 2025
24. KELLNER CH
    Electroconvulsive Therapy (ECT) for Postpartum Psychosis: Treatment for a Medical Emergency.
    Am J Psychiatry. 2025;182:1093.
    PubMed    
    
    
    
25. BERGINK V, Kamperman A, Robakis T
    Electroconvulsive Therapy (ECT) for Postpartum Psychosis: Treatment for a Medical Emergency: Response to Kellner.
    Am J Psychiatry. 2025;182:1094.
    PubMed    
    
    
    November 2025
26. KANTROWITZ JT, Mayer MR, Choo TH, Liu K, et al
    Effect Size Deflation With Increasing Sample Size in Adjunctive Trials for Negative Symptoms in Schizophrenia: A Meta-Analysis and Meta-Regression Across Mechanisms of Action.
    Am J Psychiatry. 2025 Nov 19:appiajp20250034. doi: 10.1176/appi.ajp.20250034.
    PubMed     Abstract available
    
    
    
27. LANG U, Metsala J, Ramsay H, Boland F, et al
    Doxycycline Use in Adolescent Psychiatric Patients and Risk of Schizophrenia: An Emulated Target Trial.
    Am J Psychiatry. 2025 Nov 5:appiajp20240958. doi: 10.1176/appi.ajp.20240958.
    PubMed     Abstract available
    
    
    
28. KALIN NH
    Schizophrenia, Alcohol Use Disorder, and Stimulant Use Disorder.
    Am J Psychiatry. 2025;182:957-959.
    PubMed    
    
    
    
29. YALCINBAS EA, Ajanaku B, Nelson ED, Garcia-Flores R, et al
    Transcriptomic Analysis of the Human Habenula in Schizophrenia.
    Am J Psychiatry. 2025;182:991-1006.
    PubMed     Abstract available
    
    
    
30. GUR RE
    Pathways to Psychosis: Factors Associated With Risk for Psychosis Spectrum Disorders.
    Am J Psychiatry. 2025;182:984-990.
    PubMed    
    
    
    October 2025
31. ZHAO G, Sun Y, Zhang Y, Lu T, et al
    Efficacy and Tolerability of Seven Antipsychotic Drugs in Acutely Ill Patients With Schizophrenia: A Randomized, Multicenter, Assessor-Blinded Trial.
    Am J Psychiatry. 2025 Oct 29:appiajp20250111. doi: 10.1176/appi.ajp.20250111.
    PubMed     Abstract available
    
    
    
32. HOWES OD, Bukala BR, Chen EYH, Correll CU, et al
    Relapse in Schizophrenia: A Systematic Review of Criteria for Clinical Studies and International Consensus Guidelines to Improve Them.
    Am J Psychiatry. 2025 Oct 8:appiajp20241040. doi: 10.1176/appi.ajp.20241040.
    PubMed     Abstract available
    
    
    September 2025
33. KALIN NH
    Scientific Advances Relevant to Schizophrenia, Psychosis, and the Treatment of Methamphetamine Use Disorder.
    Am J Psychiatry. 2025;182:797-800.
    PubMed    
    
    
    
34. HORAN WP, Harvey PD, Brannan SK
    Does Xanomeline/Trospium Have Unique Benefits for Cognitive Impairment Associated With Schizophrenia? Response to Tandon.
    Am J Psychiatry. 2025;182:878-879.
    PubMed    
    
    
    
35. CASSIDY C, Wang Y, Abi-Dargham A
    Forging a Role for Iron in the Dopamine Dysfunction of Schizophrenia.
    Am J Psychiatry. 2025;182:804-806.
    PubMed    
    
    
    
36. VANO LJ, McCutcheon RA, Sedlacik J, Kaar SJ, et al
    Reduced Brain Iron and Striatal Hyperdopaminergia in Schizophrenia: A Quantitative Susceptibility Mapping MRI and PET Study.
    Am J Psychiatry. 2025;182:830-839.
    PubMed     Abstract available
    
    
    
37. TANDON R
    Does Xanomeline/Trospium Have Unique Benefits for Cognitive Impairment Associated With Schizophrenia?
    Am J Psychiatry. 2025;182:878.
    PubMed    
    
    
    
38. ANGLIN DM, Olfson M, van der Ven E, Oh H, et al
    Neighborhood Social Vulnerability and Racial Disparities in Schizophrenia Spectrum Disorder Prevalence.
    Am J Psychiatry. 2025;182:850-860.
    PubMed     Abstract available
    
    
    July 2025
39. AHN Y, Kim J, Jung K, Lee DJ, et al
    Relationship Between Problematic Alcohol Use and Various Psychiatric Disorders: A Genetically Informed Study.
    Am J Psychiatry. 2025;182:671-682.
    PubMed     Abstract available
    
    
    June 2025
40. WARD HB, Beermann A, Manzanarez Felix K, Narisetti L, et al
    Grip Strength as a Marker of Resting-State Network Integrity and Well-Being in Early Psychosis.
    Am J Psychiatry. 2025 Jun 25:appiajp20240780. doi: 10.1176/appi.ajp.20240780.
    PubMed     Abstract available
    
    
    
41. KALIN NH
    Depression, Inflammation, and Postpartum Psychosis.
    Am J Psychiatry. 2025;182:501-503.
    PubMed    
    
    
    
42. DAZZAN P
    A Step Closer to Understanding Familial Risk for Postpartum Psychosis.
    Am J Psychiatry. 2025;182:504-505.
    PubMed    
    
    
    May 2025
43. ZHANG L, Ivleva EI, Parker DA, Hill SK, et al
    Impact of Polygenic Interactions With Anticholinergic Burden on Cognition and Brain Structure in Psychosis Spectrum Disorders.
    Am J Psychiatry. 2025 May 28:appiajp20240709. doi: 10.1176/appi.ajp.20240709.
    PubMed     Abstract available
    
    
    
44. KEPINSKA AP, Robakis TK, Humphreys K, Liu X, et al
    Familial Risk of Postpartum Psychosis.
    Am J Psychiatry. 2025 May 19:appiajp20230576. doi: 10.1176/appi.ajp.20230576.
    PubMed     Abstract available
    
    
    April 2025
45. CHENGAPPA KNR, Gannon JM, Joshi YB
    A Call to Psychiatrists: Deprescription of Unnecessary Anticholinergic Medications in Schizophrenia Must Start Now.
    Am J Psychiatry. 2025;182:319-321.
    PubMed    
    
    
    
46. PERLIS RH
    Targeting Schizophrenia.
    Am J Psychiatry. 2025;182:329-331.
    PubMed    
    
    
    
47. ORHAN F, Malwade S, Khanlarkhani N, Gkogka A, et al
    Kynurenic Acid and Promotion of Activity-Dependent Synapse Elimination in Schizophrenia.
    Am J Psychiatry. 2025;182:389-400.
    PubMed     Abstract available
    
    
    
48. ZHOU L, Sommer IEC, Yang P, Sikirin L, et al
    What Do Four Decades of Research Tell Us About the Association Between Childhood Adversity and Psychosis: An Updated and Extended Multi-Level Meta-Analysis.
    Am J Psychiatry. 2025;182:360-372.
    PubMed     Abstract available
    
    
    
49. KALIN NH
    Psychotic Disorders and Schizophrenia: Treatment, Risk, Brain Alterations, and Mechanisms.
    Am J Psychiatry. 2025;182:313-315.
    PubMed    
    
    
    
50. NEUFELD NH, Blumberger DM
    An Update on the Use of Neuromodulation Strategies in the Treatment of Schizophrenia.
    Am J Psychiatry. 2025;182:332-340.
    PubMed     Abstract available
    
    
    March 2025
51. CORLETT PR, Fraser KM
    20 Years of Aberrant Salience in Psychosis: What Have We Learned?
    Am J Psychiatry. 2025 Mar 26:appiajp20240556. doi: 10.1176/appi.ajp.20240556.
    PubMed     Abstract available
    
    
    
52. KALIN NH
    New Developments in the Treatment of Depression, OCD, and Schizophrenia.
    Am J Psychiatry. 2025;182:223-226.
    PubMed    
    
    
    
53. JAVITT DC
    Xanomeline-Trospium Treatment of Cognitive Impairments of Schizophrenia: Hope for Some, or Hope for All?
    Am J Psychiatry. 2025;182:237-239.
    PubMed    
    
    
    February 2025
54. OMLOR W, Rabe F, Fuchs S, Surbeck W, et al
    Estimating Multimodal Structural Brain Variability in Schizophrenia Spectrum Disorders: A Worldwide ENIGMA Study.
    Am J Psychiatry. 2025 Feb 26:appiajp20230806. doi: 10.1176/appi.ajp.20230806.
    PubMed     Abstract available
    
    
    
55. MANCINI V, Latreche C, Fanshawe JB, Varvari I, et al
    Anticholinergic Burden and Cognitive Function in Psychosis: A Systematic Review and Meta-Analysis.
    Am J Psychiatry. 2025 Feb 26:appiajp20240260. doi: 10.1176/appi.ajp.20240260.
    PubMed     Abstract available
    
    
    
56. TIIHONEN J, Tanskanen A, Solmi M, Rubio JM, et al
    Continuous Dopamine D(2) Receptor Blockade and Long-Term Outcome in First-Episode Schizophrenia.
    Am J Psychiatry. 2025 Feb 19:0. doi: 10.1176/appi.ajp.20240321.
    PubMed     Abstract available
    
    
    December 2024
57. HORAN WP, Sauder C, Harvey PD, Ramsay IS, et al
    The Impact of Xanomeline and Trospium Chloride on Cognitive Impairment in Acute Schizophrenia: Replication in Pooled Data From Two Phase 3 Trials.
    Am J Psychiatry. 2024 Dec 11. doi: 10.1176/appi.ajp.20240076.
    PubMed     Abstract available
    
    
    October 2024
58. GALLUCCI J, Yu JC, Oliver LD, Nakua H, et al
    Neural Circuitry and Therapeutic Targeting of Depressive Symptoms in Schizophrenia Spectrum Disorders.
    Am J Psychiatry. 2024;181:910-919.
    PubMed     Abstract available
    
    
    
59. REILLY TJ, McCutcheon RA
    Menopausal Hormone Therapy for Women With Schizophrenia: What's Stopping Us?
    Am J Psychiatry. 2024;181:854-855.
    PubMed    
    
    
    
60. KRAMER EN, Velicu V
    Aripiprazole Augmentation as a Treatment for Clozapine-Induced Weight Gain.
    Am J Psychiatry. 2024;181:935-936.
    PubMed    
    
    
    
61. CHENGAPPA KNR, Cotes RO
    Clozapine's High Incidence of Ileus and Pneumonia Demand Better Clinical Strategies-How Do We Get There?
    Am J Psychiatry. 2024;181:851-853.
    PubMed    
    
    
    
62. MCINTYRE RS, Kwan ATH, Rosenblat JD, Teopiz KM, et al
    Aripiprazole Augmentation as a Treatment for Clozapine-Induced Weight Gain: Response to Kramer and Velicu.
    Am J Psychiatry. 2024;181:936-937.
    PubMed    
    
    
    
63. HWANG M, Brady R
    Neural Circuitry and Therapeutic Targeting of Depressive Symptoms in Schizophrenia Spectrum Disorders.
    Am J Psychiatry. 2024;181:858-860.
    PubMed    
    
    
    
64. ARNSTEN AFT, Datta D
    Characterizing the Most Vulnerable Prefrontal Cortical Neurons in Schizophrenia.
    Am J Psychiatry. 2024;181:861-864.
    PubMed    
    
    
    
65. TAMMINGA CA
    Psychosis Risk With Prescription Amphetamine.
    Am J Psychiatry. 2024;181:856-857.
    PubMed    
    
    
    
66. KALIN NH
    Schizophrenia Spectrum Disorders and Psychosis.
    Am J Psychiatry. 2024;181:847-850.
    PubMed    
    
    
    
67. LEUCHT S, Priller J, Davis JM
    Antipsychotic Drugs: A Concise Review of History, Classification, Indications, Mechanism, Efficacy, Side Effects, Dosing, and Clinical Application.
    Am J Psychiatry. 2024;181:865-878.
    PubMed     Abstract available
    
    
    
68. ARION D, Enwright JF 3rd, Gonzalez-Burgos G, Lewis DA, et al
    Cell Type-Specific Profiles and Developmental Trajectories of Transcriptomes in Primate Prefrontal Layer 3 Pyramidal Neurons: Implications for Schizophrenia.
    Am J Psychiatry. 2024;181:920-934.
    PubMed     Abstract available
    
    
    September 2024
69. PARTANEN JJ, Happola P, Kampe A, Ahola-Olli A, et al
    High Burden of Ileus and Pneumonia in Clozapine-Treated Individuals With Schizophrenia: A Finnish 25-Year Follow-Up Register Study.
    Am J Psychiatry. 2024 Sep 12:appiajp20230744. doi: 10.1176/appi.ajp.20230744.
    PubMed     Abstract available
    
    
    
70. MORAN LV, Skinner JP, Shinn AK, Nielsen K, et al
    Risk of Incident Psychosis and Mania With Prescription Amphetamines.
    Am J Psychiatry. 2024 Sep 12:appiajp20230329. doi: 10.1176/appi.ajp.20230329.
    PubMed     Abstract available
    
    
    
71. BRAND BA, Sommer IE, Gangadin SS, Tanskanen A, et al
    Real-World Effectiveness of Menopausal Hormone Therapy in Preventing Relapse in Women With Schizophrenia or Schizoaffective Disorder.
    Am J Psychiatry. 2024 Sep 12:appiajp20230850. doi: 10.1176/appi.ajp.20230850.
    PubMed     Abstract available
    
    
    July 2024
72. JONSSON L, Horbeck E, Primerano A, Song J, et al
    Association of Occupational Dysfunction and Hospital Admissions With Different Polygenic Profiles in Bipolar Disorder.
    Am J Psychiatry. 2024;181:620-629.
    PubMed     Abstract available
    
    
    June 2024
73. KURTZ MM
    Cognitive Remediation in Schizophrenia Spectrum Illness: Evidence for Treatment Persistence.
    Am J Psychiatry. 2024;181:471-473.
    PubMed    
    
    
    
74. VANO LJ, Veronese M, McCutcheon RA, Howes OD, et al
    Neuromelanin-Sensitive MRI: A Biomarker for Treatment-Resistant Schizophrenia?
    Am J Psychiatry. 2024;181:468-470.
    PubMed    
    
    
    
75. BRENNAND KJ
    Aligning Stem Cell Models and Postmortem Studies to Query Striatal Neurodevelopment in Schizophrenia.
    Am J Psychiatry. 2024;181:465-467.
    PubMed    
    
    
    
76. BIRNBAUM R, Weinberger DR
    The Genesis of Schizophrenia: An Origin Story.
    Am J Psychiatry. 2024;181:482-492.
    PubMed     Abstract available
    
    
    
77. KALIN NH
    Advances in Understanding Schizophrenia, ADHD, and ASD.
    Am J Psychiatry. 2024;181:461-464.
    PubMed    
    
    
    
78. TRAMAZZO S, Lian W, Ajnakina O, Carlson G, et al
    Long-Term Course of Remission and Recovery in Psychotic Disorders.
    Am J Psychiatry. 2024;181:532-540.
    PubMed     Abstract available
    
    
    May 2024
79. KANG J, Castro VM, Ripperger M, Venkatesh S, et al
    Genome-Wide Association Study of Treatment-Resistant Depression: Shared Biology With Metabolic Traits.
    Am J Psychiatry. 2024 May 15:appiajp20230247. doi: 10.1176/appi.ajp.20230247.
    PubMed     Abstract available
    
    
    April 2024
80. LIGHT GA, Swerdlow NR
    Predicting Conversion to Psychosis: What Lies Beyond the Biomarkers?
    Am J Psychiatry. 2024;181:272-274.
    PubMed    
    
    
    March 2024
81. VAN DER PLUIJM M, Wengler K, Reijers PN, Cassidy CM, et al
    Neuromelanin-Sensitive MRI as Candidate Marker for Treatment Resistance in First-Episode Schizophrenia.
    Am J Psychiatry. 2024 Mar 13:appiajp20220780. doi: 10.1176/appi.ajp.20220780.
    PubMed     Abstract available
    
    
    
82. VITA A, Barlati S, Ceraso A, Nibbio G, et al
    Durability of Effects of Cognitive Remediation on Cognition and Psychosocial Functioning in Schizophrenia: A Systematic Review and Meta-Analysis of Randomized Clinical Trials.
    Am J Psychiatry. 2024 Mar 13:appiajp20230396. doi: 10.1176/appi.ajp.20230396.
    PubMed     Abstract available
    
    
    February 2024
83. HOU Y, Xia H, He T, Zhang B, et al
    N2 Responses in Youths With Psychosis Risk Syndrome and Their Association With Clinical Outcomes: A Cohort Follow-Up Study Based on the Three-Stimulus Visual Oddball Paradigm.
    Am J Psychiatry. 2024 Feb 29:appiajp20221013. doi: 10.1176/appi.ajp.20221013.
    PubMed     Abstract available
    
    
    
84. ROGNLI EB, Hoye A, Bramness JG
    Methamphetamine-Induced Psychosis and Schizophrenia: A Call for Special Attention: Response to Zhu et al.
    Am J Psychiatry. 2024;181:168-169.
    PubMed    
    
    
    
85. ZHU L, Ni T, Guan F
    Methamphetamine-Induced Psychosis and Schizophrenia: A Call for Special Attention.
    Am J Psychiatry. 2024;181:168.
    PubMed    
    
    
    November 2023
86. SAWADA T, Barbosa AR, Araujo B, McCord AE, et al
    Recapitulation of Perturbed Striatal Gene Expression Dynamics of Donor's Brains With Ventral Forebrain Organoids Derived From the Same Individuals With Schizophrenia.
    Am J Psychiatry. 2023 Nov 2:appiajp20220723. doi: 10.1176/appi.ajp.20220723.
    PubMed     Abstract available
    
    
    
87. KALIN NH
    New Insights Into Psychotic Disorders.
    Am J Psychiatry. 2023;180:779-781.
    PubMed    
    
    
    
88. VAN DER VEN E, Susser E
    Structural Racism and Risk of Schizophrenia.
    Am J Psychiatry. 2023;180:782-784.
    PubMed    
    
    
    
89. CANNON TD
    Predicting Conversion to Psychosis Using Machine Learning: Are We There Yet?
    Am J Psychiatry. 2023;180:789-791.
    PubMed    
    
    
    
90. GOFF DC, Roffman J, Holt DJ
    Another Step Toward the Prediction of Antipsychotic Treatment Response Using Functional Connectivity.
    Am J Psychiatry. 2023;180:787-788.
    PubMed    
    
    
    
91. FORSYTH JK, Bearden CE
    Rethinking the First Episode of Schizophrenia: Identifying Convergent Mechanisms During Development and Moving Toward Prediction.
    Am J Psychiatry. 2023;180:792-804.
    PubMed    
    
    
    
92. STRAWBRIDGE RJ, Graham N
    Dissecting the Genetic Relationship Between Schizophrenia and Cardiovascular Disease.
    Am J Psychiatry. 2023;180:785-786.
    PubMed    
    
    
    
93. JOSHI Y, Swerdlow N, Light G
    Points that Need Attention in Early Auditory Information Processing Research in Schizophrenia: Response to Lin and Hsieh.
    Am J Psychiatry. 2023;180:841-842.
    PubMed    
    
    
    October 2023
94. SMUCNY J, Davidson I, Carter CS
    Are We There Yet? Predicting Conversion to Psychosis Using Machine Learning.
    Am J Psychiatry. 2023 Oct 4:appiajp20220973. doi: 10.1176/appi.ajp.20220973.
    PubMed    
    
    
    September 2023
95. RODEVAND L, Rahman Z, Hindley GFL, Smeland OB, et al
    Characterizing the Shared Genetic Underpinnings of Schizophrenia and Cardiovascular Disease Risk Factors.
    Am J Psychiatry. 2023 Sep 27:appiajp20220660. doi: 10.1176/appi.ajp.20220660.
    PubMed     Abstract available
    
    
    
96. KUMAR K, Modenato C, Moreau C, Ching CRK, et al
    Subcortical Brain Alterations in Carriers of Genomic Copy Number Variants.
    Am J Psychiatry. 2023;180:685-698.
    PubMed     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Schizophrenia is free of charge. Privacy / Datenschutzerklärung | Imprint / Impressum